Expression of the soluble vascular endothelial growth factor receptor-1 in cutaneous melanoma: role in tumour progression

F. Ruffini, C.M. Failla,* A. Orecchia,* M.R. Bani,† A.S. Dorio,‡ C. Fortes,§ G. Zambruno,* G. Graziani,‡ R. Giavazzi,† S. D’Atri and P.M. Lacal

Laboratory of Molecular Oncology, *Laboratory of Molecular and Cell Biology and §Clinical Epidemiology Unit, Istituto Dermopatico dell’Immacolata-IRCCS, 00167 Rome, Italy
†Laboratory of the Biology and Treatment of Metastasis, Department of Oncology, Mario Negri Institute for Pharmacological Research, Milan, Italy
‡Department of Neuroscience, University of Rome ‘Tor Vergata’, Rome, Italy

Correspondence
Pedro M. Lacal.
E-mail: p.lacal@idi.it

Accepted for publication
21 December 2010

Funding sources
This study was supported by the Italian Ministry of Health (RF07 Onc. 25) and by a FIRB grant (RBIP061.CA9).

Conflicts of interest
None declared.

DOI 10.1111/j.1365-2133.2010.10200.x

Summary

Background Vascular endothelial growth factor (VEGF)-A, placenta growth factor (PlGF) and their corresponding membrane receptors are involved in autocrine and paracrine regulation of melanoma growth and metastasis. Besides the membrane receptors, a soluble form of the VEGF receptor (VEGFR)-1 (sVEGFR-1) has been identified, that behaves both as a decoy receptor, sequestering VEGF-A and PlGF, and as an extracellular matrix (ECM) molecule, promoting endothelial cell adhesion and migration through the interaction with α5β1 integrin.

Objectives To analyse whether sVEGFR-1 plays a role during melanoma progression.

Methods sVEGFR-1 expression was evaluated in a panel of 36 melanoma cell lines and 11 primary human melanocyte cultures by quantitative real-time polymerase chain reaction analysis and in specimens of primary or metastatic melanoma lesions from 23 patients by immunohistochemical analysis.

Results sVEGFR-1 expression was highly upregulated in melanoma cell lines with respect to human melanocytes. Interestingly, cell lines obtained from cutaneous metastases showed a significant reduction of sVEGFR-1 expression, as compared with cell lines derived from primary tumours. These results were confirmed by immunohistochemical analysis of sections from primary skin melanomas and the corresponding cutaneous metastases, suggesting that modulation of sVEGFR-1 expression influences ECM invasion by melanoma cells and metastasis localization. Moreover, we provide evidence that adhesion of melanoma cells to sVEGFR-1 is favoured by the activation of a VEGF-A/VEGFR-2 autocrine loop.

Conclusions Our data strongly suggest that sVEGFR-1 plays a role in melanoma progression and that low sVEGFR-1/VEGF-A and sVEGFR-1/transmembrane VEGFR-1 ratios might predict a poor outcome in patients with melanoma.

A critical step in melanoma progression is the transition of the primary tumour from a radial growth phase (RGP) to a vertical growth phase (VGP). The latter requires high angiogenic activity, that contributes to the metastatic dissemination of tumour cells. Melanoma cells release several angiogenic factors, including the members of the vascular endothelial growth factor (VEGF) family, VEGF-A and placenta growth factor (PlGF).

VEGF-A exerts its biological effects on endothelial cells through the interaction with two membrane tyrosine kinase receptors, VEGF receptor (VEGFR)-1 and VEGFR-2.9 VEGFR-1 and, in particular, VEGF-A expression has been correlated with the transition of melanoma lesions from the RGP to the VGP.4,5 Melanoma cells express functional receptors for these angiogenic factors, and the receptor/ligand interaction modulates cellular pathways important for melanoma cell proliferation, apoptosis and invasiveness.1,2,6–8
mainly mediates endothelial cell migration in response to the angiogenic factor, while VEGFR-2 is the major receptor involved in endothelial cell survival and proliferation and in the increase of microvascular permeability. PlGF binds exclusively to VEGFR-1 and promotes endothelial cell migration. In addition to the transmembrane form of VEGFR-1 (mVEGFR-1), endothelial cells produce a soluble form of the receptor (sVEGFR-1), deriving from an alternative splicing of the same gene transcript. sVEGFR-1, which comprises the extracellular region of mVEGFR-1 and a specific sequence of 30 amino acids at the C-terminal domain, can prevent the interaction of VEGF-A and PlGF with the tyrosine kinase transmembrane receptors. It has been demonstrated that sVEGFR-1 is sufficient to rescue vessel branching defects occurring during vasculogenesis in mVEGFR-1 knockout mice. In agreement with this finding, studies by our group demonstrated that sVEGFR-1 is a component of the extracellular matrix (ECM) and that it interacts directly with the α5β1 integrin, leading to endothelial cell adhesion and migration. Therefore, sVEGFR-1 could play distinct roles during angiogenesis, as a decoy receptor, and as a molecule involved in cell adhesion and migration.

We previously described the expression of mVEGFR-1 in melanoma cell lines, and suggested a role for this receptor in melanoma growth and invasiveness. However, no data are available so far on the expression of sVEGFR-1 in melanoma, and on its possible role during melanoma progression. In the present study, we analysed sVEGFR-1 expression in a panel of melanoma cell lines and specimens from primary and metastatic lesions. Moreover, with the purpose of evaluating whether sVEGFR-1 might be involved in melanoma cell invasion of the ECM, we analysed the ability of melanoma cells to adhere to sVEGFR-1. The results indicated a relationship between sVEGFR-1 expression and human melanoma progression and suggested that a low expression of sVEGFR-1, specifically occurring in cutaneous metastases with respect to primary melanomas or lymph node metastases, might contribute to the ability of melanoma to invade the skin.

Materials and methods

Materials

Culture media and supplements, Freund adjuvant for immunizations and reagents for hybridoma production, antibody purification and cell transfection, as well as antibodies for immunocytochemistry were purchased from Sigma (St Louis, MO, U.S.A.). Fatty acid-free bovine serum albumin was from Roche (Mannheim, Germany). VEGF-A, PlGF and antibodies used in enzyme-linked immunosorbent assays (ELISAs) were from R&D Systems (Abingdon, U.K.).

Melanoma cell lines and normal human cells

The origin of the human melanoma cell lines GR-Mel, ST-Mel, SN-Mel, CN-Mel, M14, 13443-Mel, 397-Mel, WM115, WM266-4, LCP-Mel, LCM-Mel, LB-24 and SK-Mel-28 has been described previously. CT-Mel, DR-Mel, CR-Mel, MR-Mel, CH-Mel, CL-Mel and DT-Mel cell lines were established in the Laboratory of Molecular Oncology, IDI-IRCCS (Rome, Italy). A375 cell line was purchased from the American Type Culture Collection (Manassas, VA, U.S.A.). M20 cell line was a generous gift from Dr G. Zupi (Regina Elena Cancer Institute, Rome, Italy) and INT021 cell line was a generous gift from Dr L. Rivoltini (National Cancer Institute, Milan, Italy). The remaining melanoma cell lines used in this study were kindly provided by Dr Meenhard Herlyn (The Wistar Institute, Philadelphia, PA, U.S.A.). Normal human melanocytes, human umbilical vein endothelial cells (HUVEC), human keratinocytes and the murine NIH/3T3 cell line, used as controls, were obtained as previously described.

Quantitative real-time polymerase chain reaction

Quantitative real-time reverse transcription–polymerase chain reaction (qRT-PCR) was performed by the dual-labelled fluorogenic probe method, using an ABI Prism 7000 sequence detector (PerkinElmer, Groningen, the Netherlands), and expression levels were calculated by the relative standard curve method. Primers used for qRT-PCR analysis were as follows: sVEGFR-1, forward 5‘-GAACTTTGGTGACAGGTGTTGG-3’ and reverse 5‘-CACAGAGGGCAAGGCTGCGG-3’; mVEGFR-1, forward 5‘-ACCAGATGCGACCTACTAGT-3’ and reverse 5‘-AGGCCCCTGGGTGTTGCTGTC-3’; VEGF-A, forward 5‘-GCTACTGGCAATCGATCGAG-3’ and reverse 5‘-TGTTGATTTGGAACCTCCTCA-3’; VEGFR-2, forward 5‘-GTCTATGGCATTCCTCCTCCC-3’ and reverse 5‘-GAGACAGCTTGCTGGGCT-3’. Primers are available from R&D Systems (Abingdon, U.K.).

Production of mouse anti-soluble vascular endothelial growth factor receptor-1 monoclonal antibodies

Anti-sVEGFR-1 monoclonal antibodies (mAbs) were generated by the standard hybridoma technology using BALB/c mice (Charles River, Calco, Italy) immunized with 50 μg of a MAP4 peptide (Multiple Antigenic Peptide; PRIMM, Milan, Italy), which corresponds to part of the human sVEGFR-1 unique sequence (NNKAVFSRISKFKSTRND). Hybridomas producing anti-human sVEGFR-1 mAbs were identified by ELISA using sVEGFR-1-coated 96-well plates. The IgM mAb produced by the hybridoma clone H9E6 was purified from the culture supernatant by standard protocols.

Flow cytometry analysis

Evaluation of integrin α5β1 expression was performed using the mAb JBS5 (Chemicon, Temecula, CA, U.S.A.), as previously described.

Immunohistochemical analysis

Twenty-three patients with melanoma, diagnosed between 1996 and 2001, were identified retrospectively from the
Melanoma Registry, Epidemiology Unit, IDI-IRCCS Hospital, Rome. Fourteen of the 23 patients with melanoma developed cutaneous metastases between 1998 and 2005. Four-micrometre thick sections of melanoma specimens or normal skin were deparaffinized and rehydrated. Staining procedure was performed using the TSA Biotin System (PerkinElmer), following the manufacturer’s instructions. Negative controls were obtained by omitting the primary antibody or by absorbing the primary antibody with 10 times molar excess of the MAP4 peptide.

Generation of M14C2 cells expressing vascular endothelial growth factor receptor-2 or soluble vascular endothelial growth factor receptor-1

The M14 cell line, devoid of both VEGFR-1 and VEGFR-2, was cloned by limiting dilution and one clone (M14C2) was transfected with the pcDNA3/VEGFR-2 plasmid (a generous gift of Dr K. Ballmer-Hofer, PSI, Zurich) or with the empty vector (pcDNA3). Transfection was performed using polybrene and dimethyl sulphoxide, as previously described, and transfected cells were selected in G418-containing culture medium. VEGFR-2-expressing subclones were identified by Western blot analysis using the C-20 polyclonal antibody from Santa Cruz Biotechnology (Santa Cruz, CA, U.S.A.) and HUVEC as positive control.

The sVEGFR-1 cDNA was obtained from HUVEC RNA by qRT-PCR amplification and cloned into the pBLAS49.2 plasmid (InvivoGen, San Diego, CA, U.S.A.). M14C2 cells were then transfected with the pBLAS49.2/sVEGFR-1 plasmid (M14C2/SF15 cells) or with the empty vector (M14C2/B4 cells) as described above. sVEGFR-1 expression in M14C2/SF15 cells was confirmed by Western blot analysis using the polyclonal antibody AF321 (R&D Systems), whereas the amount of polypeptide secreted into the culture supernatant was quantified by ELISA.

Results

Expression of soluble vascular endothelial growth factor receptor-1 in human melanoma cell lines

Expression of sVEGFR-1 was initially analysed by qRT-PCR in a small group of melanoma cell lines derived from primary or metastatic lesions and in three melanocyte cultures (Fig. 1). All the melanocyte cultures were negative for sVEGFR-1 mRNA, whereas this transcript was highly expressed in three of four primary melanomas (Fig. 1). On the other hand, among the eight melanoma cell lines originating from metastases, only two cell lines displayed high levels of sVEGFR-1 mRNA (Fig. 1). The release of sVEGFR-1 into the cell culture supernatant was analysed by ELISA. As illustrated in Table 1, a good correspondence was found between the expression of sVEGFR-1 mRNA and the amount of protein secreted by the melanoma cell lines.

With the aim of identifying the subset of melanoma cell lines that preferentially expresses sVEGFR-1, the mRNA levels for this VEGFR-1 isoform were evaluated by qRT-PCR in a panel of 36 melanoma cell lines, originating from primary or metastatic lesions (Fig. 2). The expression of mVEGFR-1 was also determined in the same panel of cell lines. The results indicated that 11 of 12 (92%) cell lines originating from primary tumours and 16 of 24 (67%) cell lines derived from metastatic lesions expressed sVEGFR-1 (Fig. 2). When the metastatic cell lines derived from cutaneous or lymph node metastases were analysed separately, seven of 13 (54%) cell lines established from skin metastases and nine of 11 cell lines (82%) established from lymph node metastases were found to be positive for sVEGFR-1 expression. The mVEGFR-1 transcript was highly expressed in both primary (11 of 12 cell lines, 92%) and metastatic (19 of 24 cell lines, 79%) cell lines. In particular, 69% of the cutaneous metastases (nine of 13) and 91% of the lymph node metastases (10 of 11) were positive for mVEGFR-1 (Fig. 2). Primary human melanocyte cultures
were mostly negative for the expression of both mVEGFR-1 and sVEGFR-1 (Fig. 2).

Box and whisker diagram analysis of the qRT-PCR results further evidenced that the expression of both VEGFR-1 isoforms was significantly upregulated (P < 0·05) in melanoma cells with respect to melanocytes (Fig. 3). Moreover, the cell lines established from primary tumours displayed significantly higher (P < 0·05) sVEGFR-1 and mVEGFR-1 mRNA levels than those of the cell lines derived from cutaneous metastases. No significant differences in the expression of sVEGFR-1 and mVEGFR-1 were, in contrast, observed between cell lines originating from primary tumours and lymph node metastases (Fig. 3a, b). The ratio between the expression of sVEGFR-1 and mVEGFR-1 mRNAs in each cell line was evaluated. Interestingly, the mean ratio in the cutaneous metastasis cell lines almost halved with respect to the primary melanomas (Fig. 3c).

The analysis of VEGF-A mRNA showed that primary and cutaneous metastases expressed comparably high levels of this transcript (Fig. 3d).

Soluble vascular endothelial growth factor receptor-1 expression in human melanoma specimens

To verify whether the expression of sVEGFR-1 observed in melanoma cell lines was representative of the in vivo situation and was not related to culture conditions, we then analysed primary and metastatic human melanoma specimens by immunohistochemistry using the anti-sVEGFR-1 mAb H9E6, generated in our laboratories. Specificity of H9E6 mAb for sVEGFR-1 was initially verified by ELISA as described in Materials and methods and then confirmed by immunofluorescence using a melanoma cell line (M14C2/SF15) expressing only sVEGFR-1. This cell line was obtained by transfection of a plasmid encoding sVEGFR-1 into a clone of M14 cells devoid of both VEGFR-1 and VEGFR-2 (clone M14C2). As shown in Figure 4, H9E6 mAb stained M14C2/SF15 cells, whereas it did not react with cells transfected with the empty vector (subclone M14C2/B4).

Twenty-three specimens obtained from patients with primary cutaneous melanoma, with Breslow thickness ranging from 0·8 to 9·0 mm, were then analysed for sVEGFR-1 expression. Fourteen cutaneous metastases derived from the same patients were also available. Cytoplasmic expression of sVEGFR-1 was observed in 22 of the 23 primary melanomas, although the percentage of positive tumour cells varied among the samples (Fig. 5, Table 2). Signal specificity of H9E6 was indicated by the abrogation of section staining after preincubation of the mAb with a 10-fold molar excess of the peptide used as immunogen for its production (results not shown). Notably, 10 of the 14 cutaneous metastases showed a lower level of sVEGFR-1 expression when compared with the corresponding primary melanoma (Table 2). The expression of sVEGFR-1 was also analysed in normal human skin and, consistently with previous findings,16,17 dermal endothelial cells and keratinocytes of the basal epidermal layer stained weakly with the anti-sVEGFR-1 mAb (Fig. 5).

Melanoma cell adhesion to soluble vascular endothelial growth factor receptor-1

We previously demonstrated that sVEGFR-1 secreted by endothelial cells is deposited into the ECM, and that sVEGFR-1 immobilized on a solid support can directly interact with the α5β1 integrin expressed on endothelial cells favouring cell adhesion.13 Therefore, we investigated whether melanoma cells might also be able to adhere to sVEGFR-1 using cell lines expressing high levels of α5β1 integrin (85–100% positive cells, as evaluated by flow cytometry analysis, data not shown). The results indicated that only four of nine cell lines tested adhered to sVEGFR-1 (Table 3).

As we previously demonstrated that activation of a VEGF-A/VEGFR-2 autocrine loop promotes melanoma cell invasiveness,7 we analysed the secretion of VEGF-A and the expression of VEGFR-2 by the cell lines under investigation (Table 3). Interestingly, we observed that a high sVEGFR-1 expression was associated with undetectable amounts of VEGF-A in the culture supernatants of melanoma cells (GR-Mel, WM115, DR-Mel and CR-Mel). Moreover, these cell lines and also the cell line that does not express VEGFR-2 (M14) were not able to adhere to sVEGFR-1-coated surfaces (Table 3). Therefore, we hypothesized that the simultaneous expression of VEGF-A and VEGFR-2 might be important for the adhesion of melanoma cells to sVEGFR-1.
To verify our hypothesis, the M14C2 clone, devoid of both VEGFR-1 and VEGFR-2, was stably transfected with a plasmid containing the VEGFR-2 cDNA (M14C2/MK18 sub-clone) or with the empty vector (M14C2/C4 subclone) (Fig. 6a). The transfected subclones, both secreting VEGF-A (data not shown), were then tested for their ability to adhere to sVEGFR-1. The results indicated that M14C2/MK18 cells adhered three times more efficiently to this polypeptide than M14C2/C4 cells (Fig. 6b). The improved adhesion of M14C2/MK18 cells was not due to different levels of α5β1 integrin expression, as both subclones adhered to a similar extent to fibronectin, the ECM component to which the activated α5β1 integrin preferentially binds (Fig. 6b). As shown in Figure 6b, the adhesion
Adhesion of M14C2/MK18 cells to sVEGFR-1 was significantly downmodulated by anti-VEGF-A or anti-VEGFR-2 neutralizing antibodies (Fig. 6c), further supporting the involvement of the VEGF-A/VEGFR-2 signalling pathway in the modulation of melanoma cell adhesion to sVEGFR-1.

Discussion

Previous investigations by our group have demonstrated the secretion of VEGF-A and PlGF and the expression of their membrane tyrosine kinase receptors VEGFR-1 and VEGFR-2 in a large number of melanoma cell lines. Moreover, we and others have suggested a role for these growth factors and receptors in melanoma growth and progression. However, no data are presently available on the expression of sVEGFR-1 in melanoma and on its possible role in the modulation of melanoma cell adhesion to sVEGFR-1.

sVEGFR-1 is mainly considered a negative modulator of VEGF-A and PlGF binding to VEGFR-2 and/or mVEGFR-1. Consequently, high expression of the soluble receptor during the early steps of development of a primary melanoma may hamper the ability of VEGF-A and/or PlGF to sustain tumour growth, that would depend on other factors produced by tumour cells (e.g. basic fibroblast growth factor, platelet-derived growth factor, interleukin-8). In agreement with cell lines with respect to normal melanocytes. In particular, most melanoma cell lines derived from primary tumours or lymph node metastases display high levels of sVEGFR-1 mRNA, while the transcripts for this VEGFR-1 isoform are absent or barely detectable in primary cultures of normal melanocytes. Also in cell lines established from cutaneous metastases sVEGFR-1 is upregulated with respect to melanocytes. However, the expression of this receptor, in terms of percentage of positive cell lines and transcript levels, is significantly lower as compared with cell lines derived from primary lesions or lymph node metastases. In addition, in cutaneous metastases the sVEGFR-1/mVEGFR-1 transcript ratio is decreased with respect to that observed in primary melanomas.

sVEGFR-1 in melanoma progression, F. Ruffini et al.
the results obtained in the analysis of melanoma cell lines, we observed that sVEGFR-1 is expressed, although at variable levels, in more than 90% of primary melanoma specimens. Moreover, a high percentage (71%) of the cutaneous metastases analysed showed a decrease in sVEGFR-1 expression with respect to their matched primary tumours. Progression from the primary lesion to a cutaneous metastasis might be thus favoured by the downmodulation of sVEGFR-1 expression, which would contribute to augment VEGF-A and PlGF availability. A low sVEGFR-1/VEGF-A ratio in astrocytic tumour cells has been related to a higher disease malignancy. In this context, we have previously demonstrated the involvement in melanoma invasiveness of a VEGF-A/VEGFR-2 autocrine loop that would be activated when the sVEGFR-1/VEGF-A ratio is low, and herein we found that VEGF-A is expressed at high levels in both cutaneous metastases and primary tumours. It can be hypothesized that downregulation of sVEGFR-1 expression might occur during the switch to a metastatic phenotype, that also requires high VEGF-A expression and downmodulation of the inhibitory VEGF-A isoforms.

Downregulation of sVEGFR-1 expression, instead, does not appear to be required for metastatic dissemination to the lymph nodes. Other members of the VEGF family, in particular VEGF-C, VEGF-D and their specific receptor in the lymphatic endothelial cells (VEGFR-3), are known to promote tumour spread towards the lymph nodes in various cancer types, including melanoma. Melanoma cells expressing VEGF-C induce lymphangiogenesis and lymphatic endothelial cells produce chemokines that can attract tumour cells towards the lymphatic vessels. Lymph node invasion might, therefore, be independent of sVEGFR-1 levels, as this receptor does not bind VEGF-C or VEGF-D.

In addition to the role of sVEGFR-1 as a negative modulator of VEGF-A, we previously demonstrated that this polypeptide can behave as a positive modulator of angiogenesis through its interaction with the α5β1 integrin, supporting the adhesion and migration of endothelial cells. In the present study, we found that melanoma cells may adhere to sVEGFR-1 and that this ability depends on the activation of the VEGF-A/VEGFR-2 signalling pathway. As a component of the ECM, the sVEGFR-1 produced by both endothelial and primary melanoma cells might, therefore, contribute to tumour progression sustaining neoplastic cell mobilization towards the vascular endothelium and vice versa, with consequent melanoma dissemination through the vascular system.

In regard to mVEGFR-1, our results indicate that, even though expressed at lower levels than in primary tumours, this receptor isoform is present in almost 70% of the cell lines derived from cutaneous metastases. A moderate level of mVEGFR-1 expression is probably sufficient to favour the metastatic process, as described for melanoma and for other

Fig 4. Specificity of the anti-soluble vascular endothelial growth factor receptor-1 (sVEGFR-1) monoclonal antibody (mAb) H9E6. Immunofluorescence staining of M14C2/SF15 cells (SF15), that express sVEGFR-1, and of M14C2/B4 cells (B4), that do not express this polypeptide, was utilized to analyse the specificity of mAb H9E6. Cells growing exponentially in Lab-tek chamber slides (Nalge Nunc Int., Naperville, IL, U.S.A.) were fixed in 2% formaldehyde/phosphate-buffered saline (PBS) and permeabilized with 0-5% Triton X-100/PBS. Nonspecific staining was blocked overnight with 3% bovine serum albumin (BSA)/PBS at 4 °C, before incubation with H9E6 mAb (10 μg mL⁻¹ in 3% BSA/PBS at 4 °C, overnight). Afterwards, cells were incubated with goat antimouse IgM antibody, stained with fluorescein isothiocyanate-conjugated rabbit antigoat IgG (both 1 : 100 in 3% BSA/PBS, 1 h at room temperature) and digital images were captured under a fluorescence microscope. CTR, control (not treated with mAb H9E6). Original magnification x200.
kinds of neoplasia. A broad study on the in vivo expression of this receptor isoform in melanoma specimens has been previously published, and it has been proposed that this polypeptide might have a role during melanoma progression by promoting cell migration, growth and survival. Moreover, our finding of the reduction in the sVEGFR-1/mVEGFR-1 ratio in cutaneous metastases indicates that variations of the balance between both receptor isoforms might contribute to the metastatic switch in melanoma.

Table 2. Expression of soluble vascular endothelial growth factor receptor-1 (sVEGFR-1) in cutaneous melanoma

<table>
<thead>
<tr>
<th>T categorya</th>
<th>Patient</th>
<th>Breslow thicknessb</th>
<th>Primary melanoma</th>
<th>Cutaneous metastasis</th>
</tr>
</thead>
<tbody>
<tr>
<td>T1 (&lt; 1 mm)</td>
<td>1</td>
<td>0.8</td>
<td>++</td>
<td>+/-</td>
</tr>
<tr>
<td></td>
<td>2</td>
<td>0.9</td>
<td>+/-</td>
<td>NA</td>
</tr>
<tr>
<td></td>
<td>3</td>
<td>0.95</td>
<td>+</td>
<td>NA</td>
</tr>
<tr>
<td>T2 (1.01–2 mm)</td>
<td>4</td>
<td>1.2</td>
<td>++</td>
<td>NA</td>
</tr>
<tr>
<td></td>
<td>5</td>
<td>1.6</td>
<td>++</td>
<td>++</td>
</tr>
<tr>
<td></td>
<td>6</td>
<td>1.6</td>
<td>+</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td>7</td>
<td>1.8</td>
<td>+++</td>
<td>+</td>
</tr>
<tr>
<td></td>
<td>8</td>
<td>1.8</td>
<td>+</td>
<td>NA</td>
</tr>
<tr>
<td></td>
<td>9</td>
<td>1.8</td>
<td>++</td>
<td>–/-</td>
</tr>
<tr>
<td></td>
<td>10</td>
<td>1.9</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td></td>
<td>11</td>
<td>2</td>
<td>+</td>
<td>++</td>
</tr>
<tr>
<td>T3 (2.01–4 mm)</td>
<td>12</td>
<td>2.5</td>
<td>+++</td>
<td>+</td>
</tr>
<tr>
<td></td>
<td>13</td>
<td>3</td>
<td>+++</td>
<td>+</td>
</tr>
<tr>
<td></td>
<td>14</td>
<td>3</td>
<td>+++</td>
<td>+</td>
</tr>
<tr>
<td></td>
<td>15</td>
<td>4</td>
<td>++</td>
<td>+/-</td>
</tr>
<tr>
<td></td>
<td>16</td>
<td>4</td>
<td>++</td>
<td>–/-</td>
</tr>
<tr>
<td>T4 (&gt; 4 mm)</td>
<td>17</td>
<td>6</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td>18</td>
<td>6</td>
<td>+/-</td>
<td>NA</td>
</tr>
<tr>
<td></td>
<td>19</td>
<td>7</td>
<td>+++</td>
<td>NA</td>
</tr>
<tr>
<td></td>
<td>20</td>
<td>7</td>
<td>+++</td>
<td>NA</td>
</tr>
<tr>
<td></td>
<td>21</td>
<td>8</td>
<td>+/-</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td>22</td>
<td>8.5</td>
<td>+</td>
<td>NA</td>
</tr>
<tr>
<td></td>
<td>23</td>
<td>9</td>
<td>+</td>
<td>NA</td>
</tr>
</tbody>
</table>

aAccording to the American Joint Committee on Cancer melanoma staging system. bTumour thickness (mm). cImmunoreactivity of melanoma cells: -, < 1%; +/–, > 1% and < 10%; +, > 10% and < 40%; ++, > 40% and < 80%; ++++, > 80%. NA, not available.

In conclusion, our study demonstrates for the first time that sVEGFR-1 expression is upregulated in melanoma cells and suggests that this polypeptide might play a dual role during the initial phases of melanoma progression: as a soluble polypeptide that controls tumour cell invasiveness (modulating the VEGF-A/VEGFR-2 autocrine loop) and as an ECM component, directly promoting the adhesion and migration of endothelial and tumour cells. Downregulation of sVEGFR-1 in melanoma cells might increase the availability of free VEGF-A molecules capable of interacting with its membrane receptors. Thus, a low sVEGFR-1/VEGFR-A and sVEGFR-1/mVEGFR-1 ratio might represent an indicator of poor outcome in patients with melanoma. A better understanding of the mechanisms that regulate melanoma progression might help in the design of novel and more effective strategies for the treatment of the metastatic disease, that presently has few therapeutic options. In this context, our data suggest that the efficacy as therapeutic agents in melanoma of anti-VEGF-A mAbs might be enhanced by disrupting the interaction of sVEGFR-1 with the integrin α5β1. The advantage of targeting sVEGFR-1/α5β1 integrin interaction will be two-fold: to
abrogate the function of sVEGFR-1 as adhesion molecule and to increase the availability of sVEGFR-1 as decoy receptor capable of sequestering VEGF-A.

**What’s already known about this topic?**
- The soluble form of vascular endothelial growth factor (VEGF) receptor (VEGFR)-1 (sVEGFR-1) behaves both as a decoy receptor, sequestering VEGF-A and placenta growth factor, and as an extracellular matrix (ECM) molecule, promoting endothelial cell adhesion and migration, but no data are available on the expression and possible role of this receptor isoform in melanoma progression.

**What does this study add?**
- It shows for the first time that sVEGFR-1 expression is upregulated in melanoma cells, with respect to normal melanocytes.
- It proposes a role for sVEGFR-1 during melanoma progression: as a soluble polypeptide, modulating the VEGF-A/VEGFR-2 autocrine loop, and as an ECM component, promoting tumour cell adhesion and migration.
- It suggests that low sVEGFR-1/sVEGF-A and sVEGFR-1/transmembrane VEGFR-1 ratios might predict a poor outcome in patients with melanoma.

**Acknowledgments**
The authors thank Barbara Mancini for her technical assistance in the preparation of specimens for immunohistochemical studies and Daniele Bartoloni for the artwork.
References